{"favorite_id": 10227, "calc_type": "", "dosing": false, "full_title_en": "ORBIT Bleeding Risk Score for Atrial Fibrillation", "short_title_en": "ORBIT Score for Afib", "medium_description_en": "Predicts bleeding risk in patients on anticoagulation for afib, similar to <calculator id=\"807\">HAS-BLED</calculator>.", "short_description_en": "Anticoagulation bleeding risk in afib.", "before_use": "", "instructions_en": "<p>Use in adult patients with atrial fibrillation, to assess risk of major bleeding with anticoagulation.</p>", "purpose_en": ["Prognosis", "Treatment"], "disease_en": ["Atrial Fibrillation", "Stroke/TIA"], "specialty_en": ["Cardiology", "Emergency Medicine", "Family Practice", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Arrhythmia", "Bleeding"], "system_en": ["Cardiac", "Hematologic", "Vascular"], "search_abbreviation_en": ["Orbit", "orbit score", "afib", "bleeding risk", "bleeding risk score", "bleeding risk score in afib", "orbit bleeding risk score", "ORBIT Bleeding Risk Score for Atrial Fibrillation", "ORBIT Score for Afib"], "slug": "orbit-bleeding-risk-score-atrial-fibrillation", "seo": {"meta_description_en": "The ORBIT Bleeding Risk Score for Atrial Fibrillation predicts bleeding risk in patients on anticoagulation for afib, similar to HAS-BLED.", "keywords_en": "Orbit, has-bled, stroke, bleeding risk, anticoagulation, doac, noac, coumadin, warfarin, orbit score, afib, bleeding risk score, bleeding risk score in afib, orbit bleeding risk score, ORBIT Bleeding Risk Score for Atrial Fibrillation, ORBIT Score for Afib"}, "content": {"how_to_use": {"use_case_en": "<p>Patients with atrial fibrillation in whom anticoagulation is being considered for stroke prevention.</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-0923833d-7fff-4b50-dfb8-8f0c4b589730\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ, or bleeding with a hemoglobin drop requiring transfusion of &ge;2 units (<abbr title=\"International Society on Thrombosis and Haemostasis\">ISTH</abbr> criteria).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ORBIT does not take into account choice of anticoagulant.&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Unlike <calculator id=\"807\">HAS-BLED</calculator>, ORBIT does not take into account the time in therapeutic range, as there is no reliable or readily available objective measure for therapeutic range of the direct oral anticoagulants (DOACs).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Unlike HAS-BLED, ORBIT was derived in a patient population that included vitamin K antagonists (VKAs, such as warfarin) as well as DOACs.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-ff1e8c77-7fff-6b0f-81e0-83cac0aee539\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">May be used in conjunction with the <calculator id=\"801\">CHA\u2082DS\u2082-Vasc Score</calculator> to risk stratify patients for clinically significant bleeding to help guide decisions on anticoagulation in patients with atrial fibrillation.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">May not be statistically superior to <calculator id=\"807\">HAS-BLED</calculator> (see <a href=\"#evidence\">Evidence</a> for details), but was more recently derived and validated in the era of DOACs, and may be more useful for that reason.</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "", "management_en": "", "critical_actions_en": "<p>Other risk factors not part of the ORBIT Score may influence the decision for anticoagulation. Patient preferences and values should go into the decision regarding anticoagulation as it pertains to risks vs benefits of being on anticoagulation for stroke prevention in patients with atrial fibrillation.</p>"}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"266\" /><col width=\"98\" /><col width=\"83\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Hemoglobin &lt;13 g/dL for males and &lt;12 g/dL for females, or hematocrit &lt;40% for males and &lt;36% for females</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Age &gt;74 years</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Yes</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Bleeding history*</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><calculator id=\"76\">GFR</calculator> &lt;60 mL/min/1.73 m<sup>2</sup></p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Treatment with antiplatelet agents</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>*Any history of GI bleeding, intracranial bleeding, or hemorrhagic stroke.</p>\n</div>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"172\" /><col width=\"126\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>ORBIT Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk group</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Bleeds per 100 patient-years</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0-2</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">2.4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n<td>\n<p dir=\"ltr\">Medium</p>\n</td>\n<td>\n<p dir=\"ltr\">4.7</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">4-7</p>\n</td>\n<td>\n<p dir=\"ltr\">High</p>\n</td>\n<td>\n<p dir=\"ltr\">8.1</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-4d745381-7fff-6200-cc6a-41d49ef2a07f\">From <a href=\"https://academic.oup.com/eurheartj/article/36/46/3258/2398371\" target=\"_blank\">O'Brien 2015</a>.</p>", "evidence_based_medicine_en": "<p dir=\"ltr\">In patients with atrial fibrillation, stroke prevention is a part of the management plan. The <calculator id=\"40\">CHADS\u2082</calculator> or <calculator id=\"801\">CHA\u2082DS\u2082-Vasc Score</calculator> are often used to calculate stroke risk in patients with atrial fibrillation. Stroke prevention comes in the form of aspirin or anticoagulation, depending on the risk of stroke. However, anticoagulation also creates bleeding risk. Prior existing risk calculators for risk of bleeding include <calculator id=\"807\">HAS-BLED</calculator>, <calculator id=\"1718\">ATRIA</calculator>, and others. Of these, HAS-BLED is probably the most used and well-validated.&nbsp;</p>\n<p dir=\"ltr\">With the above in mind, <a href=\"https://academic.oup.com/eurheartj/article/36/46/3258/2398371\" target=\"_blank\">O&rsquo;Brien et al (2015)</a> derived and validated the ORBIT Score as a way to assess bleeding risk in patients with atrial fibrillation. Derivation was based on data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a prospective registry of patients with atrial fibrillation across 176 sites in the United States. Of the 10,132 patients in the registry, 7,411 were analyzed (the rest were excluded for not being on oral anticoagulants or if follow-up data was lacking).&nbsp;</p>\n<p dir=\"ltr\">Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ, or bleeding with hemoglobin drop requiring transfusion of &ge;2 units. The simplified 5-item ORBIT Score was based on the 5 predictors with the strongest association with major bleeding.&nbsp;</p>\n<p dir=\"ltr\">The authors also validated the ORBIT Score with data from ROCKET-AF, a cohort of patients receiving rivaroxaban once-daily vs vitamin K antagonism. They showed that ORBIT showed better discrimination than ATRIA or HAS-BLED (c-index = 0.67, 0.66, 0.64, respectively).</p>\n<p dir=\"ltr\">However, subsequent studies in different patient populations did not show ORBIT to be superior. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26482233\" target=\"_blank\">Senoo et al (2016)</a> studied 2,293 patients in the AMADEUS trial and showed HAS-BLED to perform better in predicting major bleeding than the ORBIT score (c-index = 0.65 vs 0.61, p = 0.001). <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27557850\" target=\"_blank\">Esteve-Pastor et al (2016)</a> showed ORBIT was not superior to HAS-BLED in predicting major bleeding in 406 patients undergoing electrocardioversion (c-index = 0.82 vs 0.77, p = 0.08), or in 1,276 patients with persistent atrial fibrillation in the FANTASIIA registry (c-index = 0.70 vs 0.63, p = 0.12). <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29312640\" target=\"_blank\">Wang et al (2017)</a> conducted a meta-analysis showing that ORBIT was not superior to HAS-BLED in predicting major bleeding (8,079 total anticoagulated non-valvular atrial fibrillation patients from the United States, Britain, Spain, and the Netherlands).</p>\n<p><span id=\"docs-internal-guid-f362acac-7fff-d718-80db-65e27680e105\">Interestingly, the studies above also showed that ORBIT places more patients in the low-risk category than does HAS-BLED, thus potentially under-predicting their major bleeding risk (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26482233\" target=\"_blank\">Senoo 2016</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27557850\" target=\"_blank\">Esteve-Pastor 2016</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29312640\" target=\"_blank\">Wang 2017</a>). The concern with this is that some at-risk patients may not be flagged correctly. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29274754\" target=\"_blank\">Lip et al (2018)</a> suggest that HAS-BLED has higher sensitivity but lower specificity for major bleeding risk when compared to the ORBIT Score. As a result, care must be taken when clinically applying the results of either score. </p>", "references_list": {"Original/Primary Reference": [{"href": "https://academic.oup.com/eurheartj/article/36/46/3258/2398371 ", "text": "O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT Bleeding Score: A Simple Bedside Score to Assess Bleeding Risk in Atrial Fibrillation. Eur Heart J. 2015;36(46):3258-64."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/26482233 ", "text": "Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016;129(6):600-7."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/27557850 ", "text": "Esteve-Pastor MA, Garcia-Fernandez A, Macias M, et al. Is the ORBIT Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients? Circ J. 2016;80(10):2102-8."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/29312640", "text": "Wang C, Yu Y, Zhu W, et al. Comparing the ORBIT and HAS-BLED Bleeding Risk Scores in Anticoagulated Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. Oncotarget. 2017;8(65):109703-11."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/29274754", "text": "Lip GYH, Skjoth F, Nielsen PB, et al. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. Am J Med. 2018;131(5):574.e13-574.e27."}], "Validation": [{"href": "https://academic.oup.com/eurheartj/article/36/46/3258/2398371 ", "text": "O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT Bleeding Score: A Simple Bedside Score to Assess Bleeding Risk in Atrial Fibrillation. Eur Heart J. 2015;36(46):3258-64."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Hyunjoo Lee, MD, is a clinical assistant professor in emergency medicine at Stony Brook University Hospital. Born and raised in New York, she left New York for her undergraduate studies at Swarthmore College where she received a BA in Biology. She returned to New York and did research in B-cell biology and CLL before heading back to school to obtain her MD from Stony Brook University School of Medicine. She completed her emergency medicine residency at Mount Sinai Beth Israel in New York City and a medical education fellowship in the department of emergency medicine at Thomas Jefferson University in Philadelphia.</p>", "firstName": "Hyunjoo", "img": "https://cdn-web-img.mdcalc.com/people/hyunjoo-lee.jpg", "lastName": "Lee", "name": "Hyunjoo Lee, MD", "target": "hyunjoo-lee", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"id": 3, "name": "Dr. Emily C. O\u2019Brien", "qa_en": "", "approved": true, "priority": 0, "creator_info": {"about_en": "<p>Emily C. O\u2019Brien, PhD, is an assistant professor in population health sciences and neurology at Duke University in Durham, North Carolina. She is also a researcher in the Duke Clinical Research Institute. Dr. O\u2019Brien\u2019s primary research is focused on outcomes in cardiovascular and pulmonary disease.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-emily-o'brien.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=O%E2%80%99Brien+EC%5BAuthor%5D"}}], "reviewer": {"expert_name": [{"name": "Jeffrey Marbach, MBBS, MS, FRCPC"}]}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [{"id": 72, "order": 0, "society": "EB Medicine", "link": "https://www.ebmedicine.net/topics/hematology-oncology/anticoagulants", "text": "Calculated Decisions: ORBIT", "description": "Emergency Medicine Practice", "CalculatorId": 10227, "createdAt": "2019-11-04T17:07:20.306Z", "updatedAt": "2021-07-30T16:25:05.961Z"}], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Sex", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Male", "value": 0}, {"label": "Female", "value": 1}], "name": "sex"}, {"type": "toggle", "label_en": "Hemoglobin <13 g/dL or hematocrit <40%", "default": null, "conditionality": "sex == 0", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "name": "hemo1"}, {"type": "toggle", "label_en": "Hemoglobin <12 g/dL or hematocrit <36%", "default": null, "conditionality": "sex == 1", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "name": "hemo2"}, {"type": "toggle", "label_en": "Age >74 years", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "age"}, {"type": "toggle", "label_en": "Bleeding history", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Any history of GI bleeding, intracranial bleeding, or hemorrhagic stroke", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "name": "history"}, {"type": "toggle", "label_en": "<calculator id = \"76\">GFR</calculator> <60 mL/min/1.73 m<sup>2</sup>", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "gfr"}, {"type": "toggle", "label_en": "Treatment with antiplatelet agents", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "treatment"}], "md5": "", "cmeVersion": "10227.1", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10016, "short_title_en": "DAPT Score", "slug": "dual-antiplatelet-therapy-dapt-score"}, {"calcId": 3801, "short_title_en": "AIMS65", "slug": "aims65-score-upper-gi-bleeding-mortality"}, {"calcId": 1785, "short_title_en": "HEMORR<sub>2</sub>HAGES Score", "slug": "hemorr2hages-score-major-bleeding-risk"}]}